Illumina TruSight Oncology Assays for NovaSeq X

Illumina has launched an expanded menu of oncology assays for the NovaSeq X instrument. The high-throughput TruSight Oncology (TSO) 500 offers economic improvements, compared to the version of the assay for the NovaSeq 6000. TSO 500 ctDNA v2 enables a faster, more sensitive, and streamlined comprehensive genomic profiling workflow from blood samples for solid tumor therapy selection research. It offers improved economics, about 40 percent faster sequencing run times resulting in a three-day assay turnaround time, and more sustainable logistics, with ambient temperature shipping for consumables.